Biogen’s Spinraza, Fosun-Kite’s Yescarta and a controversial Alzheimer’s drug: All you need to know about China’s new state […]

AstraZeneca blocks investor group’s $7.6B buyout of rare disease specialist Sobi: report fkansteiner Fri, 12/03/2021 – 09:18

Fierce Pharma Asia—China’s insulin price cut; Astellas-Dyno gene therapy deal; Fujifilm’s U.K. investment aliu Fri, 12/03/2021 – 10:10

Questions posed by conservative justices of the US Supreme Court during oral arguments on 1 December have indicated […]

Thacker’s article on integrity issues in Pfizer’s vaccine trial is interesting from at least two vantage points.1 First, […]

Australia is one of the countries most at risk from climate change, but is a laggard in responding, […]

A team led by researchers at Massachusetts General Hospital (MGH) has demonstrated ​​that magnetic resonance imaging (MRI) and […]

A drug-coated balloon catheter inserted in minimally invasive cardiac surgery is increasingly serving as a replacement for the […]

In their focus on equity in the post-covid NHS, Patel and colleagues emphasise “clinical prioritisation.”1 This idea is […]

Fujifilm socks $530M into U.K. vaccine, gene therapy and microbial production, creating 350 jobs fkansteiner Wed, 12/01/2021 – […]